Monte Rosa Therapeutics Provides Corporate Update and Key An

Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously...

Related Keywords

Boston , Massachusetts , United States , Andrew Funderburk , Markus Warmuth , Cory Tromblee , Monte Rosa Qu , Monte Rosa , Exchange Commission , Monte Rosa Therapeutics Inc , Globenewswire Inc , Track Designation , Healthcare Conference , Rosa Therapeutics , Chief Executive Officer , Key Anticipated Milestones , Drug Administration Fast Track Designation , Engineered Elimination , Private Securities Litigation Reform Act , Annual Report , Markets ,